Chemo–immunotherapy with cisplatin and nivolumab as second-line approach in metastatic adrenocortical carcinoma
The combination of cisplatin and nivolumab is an active regimen in advanced, previously treated, ACC patients. The long survival achieved in this patient population with a poor prognosis is promising.
Authors
- Alfredo Berruti (ORCID: https://orcid.org/0000-0002-3956-0043)
- Deborah Cosentini (ORCID: https://orcid.org/0000-0001-8962-5020)
- Mariangela Tamburello (ORCID: https://orcid.org/0000-0001-7827-0025)
- G. Tiberio
- Andrea Abate (ORCID: https://orcid.org/0000-0002-0835-0916)
- Sandra Sigala (ORCID: https://orcid.org/0000-0003-3294-4121)
- S. Calza
- Roberta Ambrosini (ORCID: https://orcid.org/0000-0002-4082-2303)
- Rita Tinti
- S. Rodella
- Andrea Esposito
- Marta Laganà
- Giovanni Casole
- Francesca Consoli
- Salvatore Grisanti
- Davide Lorenzo Bettini
Institutions
- Surgical Specialties (Canada) (CA)
- Azienda Socio Sanitaria Territoriale degli Spedali Civili di Brescia (IT)
- University of Brescia (IT)
Publication Details
- Journal
- European Journal of Endocrinology
- Published
- 2026-01-12
- DOI
- https://doi.org/10.1093/ejendo/lvag008
- Primary Topic
- Adrenal and Paraganglionic Tumors
- Type
- article
- Field-Weighted Citation Impact
- 0.00